Buy or promote: Stock recommendation by brokers for September 1, 2025

Kotak has upgraded Clean Science to purchase from cut back with the goal value at Rs 1,370 from Rs 1,380 earlier. Analysts really feel the risk-reward ratio is now beneficial for the inventory. The inventory fell over 20% in only a month following the founding household’s 24% stake sale, which is now concluded. Analysts now discover risk-reward extra engaging, contemplating the corporate’s wholesome pipeline of progress tasks. They made modest tweaks to estimates primarily based on incremental disclosures.Nuvama maintained its purchase recommendation on Aditya Vision with the goal value at Rs 580 from Rs 503 earlier. Analysts mentioned that the corporate, after increase a big AC stock in March, confronted a weak April-June quarter (Q1FY26). To handle extra inventory, AVL halted AC orders after April. The firm has a powerful OEM help. Doubling of demonstrator incentives and dealing capital extension have been essential in clearing stock. And now the upcoming GST cuts are anticipated to enhance demand subsequent season. Analysts really feel with a powerful begin to central UP growth, per-store throughput is prone to get well to FY25 ranges by FY27.UBS has a purchase score on TVS Motor with the goal value at Rs 3,475. Analysts mentioned the launch of Orbiter, engaging priced and focusing on the youth, would strengthen its no 1 EV place. They additionally really feel competitors to heat-up within the e2W area with the latest launches.Motilal Oswal Securities maintained its purchase recommendation on Dr Agarwal’s Health Care with the goal value at Rs 530. Analysts mentioned the proposed merger of Dr Agarwal Eye Hospital and Dr Agarwal Healthcare to drive EPS accretion. The completion of the merger is predicted in 12-24 months, topic to approvals. They mentioned on a pro-forma foundation, minority curiosity associated to the 28% stake of public shareholding in AEHL might be eradicated.Investec maintained its promote recommendation on Indigo with the goal value at Rs 4,050, a draw back of about 29%. Analysts mentioned the inventory’s valuations are already pricing in aggressive progress via FY30 whereas earnings momentum is weakening. They additionally really feel any further provide might weigh on the inventory value.(Disclaimer: The opinions, analyses and proposals expressed herein are these of brokerage and don’t replicate the views of The Times of India. Always seek the advice of with a professional funding advisor or monetary planner earlier than making any funding choices.)